Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07469059

Characterization of Renal Microvascular Alterations in Patients With Active Urinary Sediment and/or Proteinuria Using Ultrasound Localization Microscopy

The goal of this study is the non-invasive visualization and quantification of renal microvascular dynamics in adult kidneys with proteinuria and/or active sediment.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University Hospital Erlangen

Erlangen, Bavaria, 91054, Germany

Location status: Recruiting

About this study

In this study, the microvascular architecture of the kidney in adults with active urinary sediment or proteinuria is to be examined non-invasively using Ultrasound Localization Microscopy (ULM).

Kidney diseases can broadly be classified according to the affected nephron compartment into glomerular, tubular, and tubulointerstitial diseases. Glomerular diseases include, among others, the nephrotic and nephritic syndromes, which differ in their clinical and laboratory characteristics: while the nephrotic syndrome is typically characterized by marked proteinuria (>3.5 g/day), hypoalbuminemia, edema, and hyperlipidemia, the nephritic syndrome is dominated by hematuria with acanthocytes, mild to moderate proteinuria, arterial hypertension, and impaired renal function. Tubular and tubulointerstitial diseases, on the other hand, often manifest as acute kidney injury (e.g., in ischemic or toxic injury), polyuria, salt wasting, or metabolic acidosis, often accompanied by nonspecific symptoms such as fatigue or dehydration.

In addition to these classical nephron compartments, renal vascular structures may also be primarily or secondarily affected, as in vasculitis, thrombotic microangiopathies, or hypertensive nephropathy. Although these vascular structures are not directly part of the nephron, they are functionally closely linked to it and have a significant impact on renal function.

To assess kidney status, pathophysiology, and the site of injury non-invasively, urinary sediment is analyzed. Urinary sediment represents a central diagnostic tool that provides information on the localization of kidney damage, thereby functioning as a type of "liquid biopsy."

If there is clinical suspicion of acute or rapidly progressive renal failure, nephrotic syndrome, significant non-nephrotic proteinuria, glomerular hematuria, or if a systemic disease with possible renal involvement is present, a kidney biopsy is usually indicated for further diagnostic clarification. Obtaining tissue samples for histological examination is an invasive procedure associated with inpatient hospitalization, considerable burden for patients, and potential complications. Currently, alternative imaging methods cannot replace kidney biopsy. Furthermore, CT, PET, or MR imaging is associated with radiation exposure or considerable additional effort (e.g., sedation).

Ultrasound Localization Microscopy (ULM) enables visualization of vascular architecture using contrast-enhanced ultrasound. Recently, glomeruli-the smallest functional units of the kidney-were visualized and even counted in both rats and humans. Thus, ULM enables an assessment of renal function potentially comparable to kidney biopsy, in which glomeruli are also counted and examined. Beyond the kidney, the microvascular architecture of the human brain has also been depicted at previously unknown resolution using ULM. ULM therefore offers both qualitative and quantitative visualization of vascular architecture and perfusion dynamics. In the latest studies, 3D ULM imaging has been achieved, allowing volumetric visualization of vascular architecture and thereby overcoming the limitations of 2D imaging. This three-dimensional depiction of vascular structures may potentially provide more realistic insights into disease-related changes that would otherwise not be possible.

In the following, the term 'ULM' is used inclusively for both 2D and 3D ULM. In this study, renal function and perfusion in patients with active urinary sediment and indication for kidney biopsy will be evaluated, compared, and correlated with results from histology (biopsy), laboratory tests, and ultrasound diagnostics. If possible, a follow up assessment via ULM/CEUS after treatment (for example pharmacological therapy) will be scheduled.

With ULM the investigators aim to visualize the microvascular architecture and glomeruli, and to investigate whether differences detectable by ULM can be identified for the various causes of active sediment. In addition, the investigators seek to establish alterations in perfusion dynamics as potential imaging markers of kidney function.

In the future, this could enable non-invasive differentiation of the underlying disease and assessment of renal function, potentially reducing the need for invasive, high-risk procedures and allowing faster diagnosis in patients with an indication for kidney biopsy due to active sediment or proteinuria.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years
  • Evidence of active urinary sediment and/or proteinuria >1 g/g creatinine
  • Indication for kidney biopsy as part of study-independent diagnostics
  • Written informed consent

Exclusion criteria

  • Known allergic disposition to SonoVue®
  • Contraindication to the use of SonoVue®
  • Pregnancy
  • Breastfeeding mothers

Treatment and study plan

Primary outcomes

  1. CEUS Time intensity curves

    Time frame: baseline and up to 10 weeks after baseline

    All CEUS outcomes will be generated in order to achieve time intensity curves in contrast enhanced ultrasound analysis

  2. CEUS Measurement1

    Time frame: baseline and up to 10 weeks after baseline

    PE (Peak-Enhancement) is an established measurement in CEUS analysis. It describes the highest signal intensity after administration of contrast agents and is measured in arbitrary units.

    All CEUS measurements are established measurements in Time intensity analysis (TIC) of contrast enhanced ultrasound data.

  3. CEUS Measurement2

    Time frame: Baseline and up to 10 weeks after baseline

    Description: WiAUC (Wash-in Area Under the Curve (AUC(TI: TTP)))

  4. CEUS Measurement 3

    Time frame: Baseline and up to 10 weeks after baseline

    RT (Rise Time = arterial inflow until maximum signal intensity), measured in seconds, higer RT means faster arterial inflow

  5. CEUS Measurement5

    Time frame: Baseline and up to 10 weeks after baseline

    mTT (mean Transit Time local) (mTT-TI))

  6. CEUS Measurement6

    Time frame: Baseline and up to 10 weeks after baseline

    TTP (Time to Peak)

  7. CEUS Measurement7

    Time frame: Baseline and up to 10 weeks after baseline

    WiR (Wash-in-Rate )

  8. CEUS Measurement8

    Time frame: Baseline and up to 10 weeks after baseline

    WiPI (Wash-in Perfusion Index (WiAUC/RT))

  9. CEUS Measurement9

    Time frame: Baseline and up to 10 weeks after baseline

    WoAUC (Wash-out AUC (AUC(TTP:TO)))

  10. CEUS Measurement10

    Time frame: Baseline and up to 10 weeks after baseline

    WiWoAUC (Wash-in- und Wash-out-AUC (WiAUC+WoAUC))

  11. CEUS Measurement11

    Time frame: Baseline and up to 10 weeks after baseline

    FT (Fall Time - (TO-TTP))

  12. CEUS Measurement12

    Time frame: Baseline and up to 10 weeks after baseline

    WOR (Wash-out-Rate) QOF (Quality Of Fit between the echo-power signal and f(t)

  13. CEUS Measurement13

    Time frame: Baseline and up to 10 weeks after baseline

    QOF (Quality Of Fit between the echo-power signal and f(t)

  14. Visualization and quantification of kidney perfusion with CEUS

    Time frame: Baseline and up to 10 weeks after baseline

    CEUS imaging for kidney perfusion in kidney disease

  15. Visualization and quantification of kidney mikrovaskularisation with ULM

    Time frame: Baseline and up to 10 weeks after baseline

    ULM imaging for kidney perfusion and microvaskularisation in kidney disease

  16. Visualization and quantification of glomeruli in the kidney with ULM

    Time frame: Baseline and up to 10 weeks after baseline

    ULM imaging for glomeruli in the kidney

Secondary outcomes

  1. ULM and Ultrasound

    Time frame: Baseline and up to 10 weeks after baseline

    Correlation of the vascular architecture visualized by ULM and parameters of quantified microvascular perfusion dynamics of the kidney (e.g., number of segmented glomeruli) with sonographic parameters (including resistance index a.o.)

  2. ULM and CEUS

    Time frame: Baseline and up to 10 weeks after baseline

    Correlation of the vascular architecture visualized by ULM and parameters of quantified microvascular perfusion dynamics of the kidney (e.g., number of segmented glomeruli) with parameters of contrast-enhanced ultrasound (CEUS)

  3. ULM and biopsy

    Time frame: Baseline and up to 10 weeks after baseline

    Correlation of the vascular architecture visualized by ULM and parameters of quantified microvascular perfusion dynamics of the kidney (including the number of segmented glomeruli) with histological parameters.

  4. 2D and 3D ULM

    Time frame: Baseline and up to 10 weeks after baseline

    Comparison of visualized and quantified microvascular dynamics (including glomeruli) using 2D and 3D ULM

  5. ULM and diagnosis

    Time frame: Baseline and up to 10 weeks after baseline

    Comparison of the vascular architecture visualized by ULM (including the number of segmented glomeruli) with the underlying diagnosis in patients with active sediment and/or proteinuria >1 g/g creatinine and indication for kidney biopsy.

  6. Comparison before and after treatment

    Time frame: Baseline and up to 10 weeks after baseline

    Comparison of microvascular dynamics via ULM/CEUS in the kidney before and after treatment (e.g., pharmacological therapy)

  7. Correlation between ULM and laboratory parameters

    Time frame: Baseline and up to 10 weeks after baseline

    Correlation of the vascular architecture visualized by ULM and parameters of quantified microvascular perfusion dynamics of the kidney (e.g., number of segmented glomeruli) with laboratory parameters (including kidney function parameters, inflammatory markers, immunological parameters.

  8. ULM on different diagnoses

    Time frame: Baseline and up to 10 weeks after baseline

    Comparison of the vascular architecture visualized by ULM and parameters of quantified microvascular perfusion dynamics of the kidney (e.g., number of segmented glomeruli) between different diagnoses.

  9. Assessment of renal function GFR

    Time frame: Baseline and up to 10 weeks after baseline

    GFR (ml/min/1,73 m2)

  10. Assessment of renal function urea

    Time frame: Baseline and up to 10 weeks after baseline

    urea (mg/dl)

Other outcomes

  1. urinary status

    Time frame: Baseline and up to 10 weeks after baseline

    levels of erythrocytes and proteinuria in urine, microscopic examination of urine sediment

Study contacts

Contact information is provided by the study sponsor or research team.

Ferdinand Knieling, MD, PhD, MHBA

CONTACT

[email protected]

091318533118

Henriette Mandelbaum, MD, PhD

CONTACT

[email protected]

09131 85 33118

Sponsors and collaborators

Lead sponsor

University of Erlangen-Nürnberg Medical School

Other

Registry information

Acronym: VARIOUS

Important dates

Study start
2025
Primary completion
2027
Study completion
2028
First posted
Mar 13, 2026
Registry last updated
Mar 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.